Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback